Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 5, 2012, Pages 834-841

  Lombard, Marli C ^a   N'Da, David D ^a   Breytenbach, Jaco C ^a   Kolesnikova, Natasha I ^b   Tran Van Ba, Christophe ^c   Wein, Sharon ^c   Norman, Jennifer ^d   Denti, Paolo ^d   Vial, Henri ^c   Wiesner, Lubbe ^d  

^a NORTH WEST UNIVERSITY   (South Africa)

^b Future production Chemicals Cluster   (South Africa)

^c CNRS   (France)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anticancer properties; Artemisinin; Hybrid dimer; In vivo antiplasmodial activity; Malaria; Pharmacokinetics

Indexed keywords

ARTEMISININ; DIMER; ETOPOSIDE; HYBRID DIMER; QUINOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL LINE, TUMOR; HUMANS; MALARIA; MALE; MICE; MICE, INBRED C57BL; PARASITEMIA; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84868677359     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.09.019     Document Type: Article

References (28)

1. M. Ashton, T.N. Hai, N.D. Sy, D.X. Huong, N. Van Huong, N.T. Niêu, and L.D. Công Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults Drug Metab. Dispos. 26 1998 25 27 (Pubitemid 28071320)
2. S. Asimus, D. Elsherbiny, T.N. Hai, B. Jansson, N.V. Huong, M.G. Petzold, U.S.H. Simonsson, and M. Ashton Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects Fundam. Clin. Pharmacol. 21 2007 307 316 (Pubitemid 46800472)
3. S. Asimus, and T. Gordi Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model Br. J. Clin. Pharmacol. 63 2007 758 762 (Pubitemid 46753577)
4. D. Barkan, H. Ginsburg, and J. Golenser Optimisation of flow cytometric measurement of parasitaemia in plasmodium-infected mice Int. J. Parasitol. 30 2000 649 653 (Pubitemid 30209951)
5. K.T. Batty, P.L. Gibbons, T.M.E. Davis, and K.F. Ilett Pharmacokinetics of dihydroartemisinin in a murine malaria model Am. J. Tropic. Med. Hyg. 78 2008 641 642 (Pubitemid 351845170)
6. V.I. Carrara, J. Zwang, E.A. Ashley, R.N. Price, K. Stepniewska, M. Barends, A. Brockman, T. Anderson, R. McGready, L. Phaiphun, S. Proux, M. van Vugt, R. Hutagalung, K.M. Lwin, A.P. Phyo, P. Preechapornkul, M. Imwong, S. Pukrittayakamee, P. Singhasivanon, N.J. White, and F. Nosten Changes in the treatment responses to artesunate-mefloquine on the northwestern border of thailand during 13 years of continuous deployment PLoS ONE 4 2009 e4551
7. J. Chadwick, A.E. Mercer, B.K. Park, R. Cosstick, and P.M. O'Neill Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells Bioorg. Med. Chem. 17 2009 1325 1338
8. R.E. Desjardins, C.J. Canfield, J.D. Haynes, and J.D. Chulay Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique Antimicrob. Agents Chemother. 16 1979 710 718 (Pubitemid 10082023)
9. A.M. Dondorp, S. Yeung, L. White, C. Nguon, N.P.J. Day, D. Socheat, and L. von Seidlein Artemisinin resistance. Current status and scenarios for containment Nat. Rev. Micro 8 2010 272 280
10. A.M. Galal, W. Gul, D. Slade, S.A. Ross, S. Feng, M.G. Hollingshead, M.C. Alley, G. Kaur, and M.A. ElSohly Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity Bioorg. Med. Chem. 17 2009 741 751
11. J.P. Jeyadevan, P.G. Bray, J. Chadwick, A.E. Mercer, A. Byrne, S.A. Ward, B.K. Park, D.P. Williams, R. Cosstick, J. Davies, A.P. Higson, E. Irving, G.H. Posner, and P.M. O'Neill Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of10â-(2-hydroxyethyl)deoxoartemisinin J. Med. Chem. 47 2004 1290 1298 (Pubitemid 38229131)
12. S.C. Kuo, H.Z. Lee, J.P. Juang, Y.T. Lin, T.S. Wu, J.J. Chang, D. Lednicer, K.D. Paull, and C.M. Lin Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin J. Med. Chem. 36 1993 1146 1156 (Pubitemid 23159288)
13. F. Leteurtre, G. Kohlhagen, K.D. Paull, and Y. Pommier Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (losoxantrone) in the national cancer institute preclinical antitumor drug discovery screen J. Natl. Cancer Inst. 86 1994 1239 1244 (Pubitemid 24253700)
14. B. Liu, J. Chang, W.P. Gordon, J. Isbell, Y. Zhou, and T. Tuntland Snapshot PK: a rapid rodent in vivo preclinical screening approach Drug Discov. Today 13 2008 360 367 (Pubitemid 351474597)
15. M.C. Lombard, D.D. N'Da, J.C. Breytenbach, P.J. Smith, and C.A. Lategan Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity Bioorg. Med. Chem. Lett. 20 2010 6975 6977
16. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, and M. Boyd Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 83 1991 757 766
17. C.J. Murray, L.C. Rosenfeld, S.S. Lim, K.G. Andrews, K.J. Foreman, D. Haring, N. Fullman, M. Naghavi, R. Lozano, and A.D. Lopez Global malaria mortality between 1980 and 2010: a systematic analysis Lancet 379 2012 413 431
18. V. Navaratnam, S.M. Mansor, N. Sit, J. Grace, Q. Li, and P. Olliaro Pharmacokinetics of artemisinin-type compounds Clin. Pharmacokinet. 39 2000 255 270
19. G.H. Posner, J. Northrop, I. Paik, K. Borstnik, P. Dolan, T.W. Kensler, S. Xie, and T.A. Shapiro New chemical and biological aspects of artemisinin-derived trioxane dimers Bioorg. Med. Chem. 10 2002 227 232 (Pubitemid 33103749)
20. G.H. Posner, P. Ploypradith, W. Hapangama, D. Wang, J.N. Cumming, P. Dolan, T.W. Kensler, D. Klinedinst, T.A. Shapiro, QunYi. Zheng, C.K. Murray, L.G. Pilkington, L.R. Jayasinghe, J.F. Bray, and R. Daughenbaugh Trioxane dimers have potent antimalarial, antiproliferative and antitumor activities in vitro Bioorg. Med. Chem. 5 1997 1257 1265 (Pubitemid 27321210)
21. A.S. Rosenthal, X. Chen, J.O. Liu, D.C. West, P.J. Hergenrother, T.A. Shapiro, and G.H. Posner Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfoneswhich are also selectively and powerfully cytotoxic to cancer cells J. Med. Chem. 52 2009 1198 1203
22. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112 (Pubitemid 20213250)
23. D. Slade, A.M. Galal, W. Gul, M.M. Radwan, S.A. Ahmed, S.I. Khan, B.L. Tekwani, M.R. Jacob, S.A. Ross, and M.A. ElSohly Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers Bioorg. Med. Chem. 17 2009 7949 7957
24. L.H. Stockwin, B. Han, S.X. Yu, M.G. Hollingshead, M.A. ElSohly, W. Gul, D. Slade, A.M. Galal, and D.L. Newton Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction Int. J. Cancer 125 2009 1266 1275
25. W. Trager, and J.B. Jensen Human malaria parasite in continuous culture Science 193 1976 673 675
26. N.J. White Antimalarial drug resistance J. Clin. Invest. 113 2004 1084 1092 (Pubitemid 38544090)
27. J. Xing, H. Yan, R. Wang, L. Zhang, and S. Zhang Liquid chromatography-tandem mass spectrometry assay for the quantitation of β-dihydroartemisinin in rat plasma J. Chromatogr. B 852 2007 202 207 (Pubitemid 46830105)
28. J. Zhang, T.D.Y. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen 4 1999 67 73 (Pubitemid 29278954)